Pharmaceuticals

A massive €40 million seed round for an Italian biotech signals a paradigm shift in treating intractable genetic disorders like Fragile X Syndrome.

Azurity's newly approved liquid lamotrigine isn't just a convenience—it's a critical safety measure for pediatric epilepsy and bipolar patients facing high risks.

How two Sydney compounding pharmacists built a multi-million-unit wellness empire by weaponizing regulatory compliance and rejecting offshore manufacturing.

As GLP-1s and complex biologics strain global supply chains, a massive 10-line expansion in Germany redefines the strategic value of sterile fill-and-finish.

Lupin’s tentative FDA approval for a liquid alternative to Eliquis highlights a strategic pivot toward value-added formulations and onshore manufacturing.

SCIEX introduces compliance software, an open API, and high-resolution oligo kits to the BioPhase 8800, accelerating mRNA therapeutic development.

As Europe embraces small modular reactors and radiopharmaceuticals, Mirion Technologies shifts its flagship safety summit to capture a booming market.

Ontario’s decision to fund a targeted adult pneumococcal vaccine offers a vital shield for seniors while easing the severe strain on our hospital systems.

A new partnership highlights how enzymatic synthesis could solve the scaling and stereochemistry crises facing next-generation RNA therapeutics.

As BioAge prepares for major investor conferences, the biotech firm is nearing a critical Phase 2 readout that could redefine cardiometabolic and obesity care.

ADARx Pharmaceuticals just executed one of 2026's largest biotech debuts. Here is why institutional capital and AbbVie are betting big on the siRNA frontier.

As CMS prepares to overhaul Medicare Part D contracting, a diverse coalition of specialty pharmacies is mobilizing data to redefine the industry's future.

As the global autoimmune market surges toward $322 billion, pharma giants are abandoning legacy biologics for precision therapies and cellular immune resets.

As clinical trials face strict FDA diversity mandates, Cedar Health Research appoints former SWK Holdings CEO Jody Staggs to scale its community-based network.

As global myopia rates surge, the FDA faces a high-stakes showdown over Sydnexis's SYD-101. The outcome will redefine pediatric eye care and supply chains.

Marathon Fusion proposes a novel supply chain hack using a stable precursor to solve the multi-decade shortage of a promising cancer-treating radioisotope.

Ozari Health’s new top ranking highlights a shift toward supply chain transparency, but regulatory hurdles and hidden costs complicate the weight-loss boom.

Applying advanced pharmacokinetic simulations, Luye Pharma is challenging a $2.9 billion market by proposing flexible dosing strategies for its antipsychotic ERZOFRI.

Crystalys Therapeutics names Tim Walbert as Chairman, signaling a bold commercial push for its de-risked gout therapy dotinurad as it enters Phase 3 trials.

Ophirex's Phase 2 trial missed its primary goals, but subgroup data and a rare FDA pathway could salvage a game-changing oral snakebite treatment.